| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 27, 2024 |
| Accession Number: | 0000950170-24-020208 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – – Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,
– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN
– Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera's patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ende
WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to
WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl
Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member. "HDAX's platform technology has great potential to deliver breakthrough treatments where there is high unmet need.""We are please
WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company's commercial strategy. Ms. McCourt will report to Jeffrey Hackman, Chairman and CEO, and serve on the Company's executive leadership te
EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)
EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)
EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)
4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)
SC 13D - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)
SC 13D/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)
SC 13G/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)
4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)
3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)
4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)
Gainers Comera Life Sciences (NASDAQ:CMRA) stock increased by 11.6% to $0.28 during Friday's after-market session. The company's market cap stands at $8.5 million. The company's, Q3 earnings came out yesterday. SenesTech (NASDAQ:SNES) stock rose 9.51% to $0.26. As per the press release, Q3 earnings came out yesterday. Aravive (NASDAQ:ARAV) stock rose 9.44% to $0.14. Aravive's trading volume hit 68.8K shares by close, accounting for 0.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 8.67% to $2.13. The market value of their outstanding shares is at $1.2 million. Co
Comera Life Sciences (NASDAQ:CMRA) reported quarterly losses of $(0.10) per share. This is a 50 percent increase over losses of $(0.20) per share from the same period last year. The company reported $136.31 thousand in sales this quarter. This is a 41.98 percent decrease over sales of $234.92 thousand the same period last year.
Gainers LianBio (NASDAQ:LIAN) shares moved upwards by 128.1% to $3.17 during Tuesday's regular session. Trading volume for this security as of 13:31 EST is 77.9 million, which is 39428.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $339.7 million. TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 45.24% to $0.44. Trading volume for this security as of 13:31 EST is 41.4 million, which is 1166.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.3 million. ImmunityBio (NASDAQ:IBRX) shares increased by 27.92% to $1.83. The current volume of 21.9 million shares is 827.8% of Immunity